Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Chemo for Neoadjuvant HNSCC
NCT06366945Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen Memorial Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06366945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366945.